Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

(Redirected from ACCOMPLISH)
Jump to: navigation, search

WikiDoc Resources for Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

Articles

Most recent articles on Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

Most cited articles on Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

Review articles on Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

Articles on Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

Images of Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

Photos of Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

Podcasts & MP3s on Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

Videos on Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

Evidence Based Medicine

Cochrane Collaboration on Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

Bandolier on Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

TRIP on Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

Clinical Trials

Ongoing Trials on Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension at Clinical Trials.gov

Trial results on Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

Clinical Trials on Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

NICE Guidance on Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

NHS PRODIGY Guidance

FDA on Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

CDC on Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

Books

Books on Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

News

Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension in the news

Be alerted to news on Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

News trends on Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

Commentary

Blogs on Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

Definitions

Definitions of Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

Patient Resources / Community

Patient resources on Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

Discussion groups on Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

Patient Handouts on Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

Directions to Hospitals Treating Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

Risk calculators and risk factors for Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

Healthcare Provider Resources

Symptoms of Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

Causes & Risk Factors for Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

Diagnostic studies for Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

Treatment of Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

Continuing Medical Education (CME)

CME Programs on Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

International

Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension en Espanol

Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension en Francais

Business

Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension in the Marketplace

Patents on Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension

Experimental / Informatics

List of terms related to Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension


Complete Title of Study

A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension

Study Acronym (The trial's abbreviation if there is one)

ACCOMPLISH

Principal Investigator, Co-investigators, and Collaborating Institutions

Study Chair: Novartis Pharmaceuticals

Overview of Trial

The goal of the ACCOMPLISH trial was to compare the effectiveness of two combination drugs (amlodipine/benazepril and benazepril/HCTZ) on reducing heart disease and death in 11,464 high risk hypertensive patients.

Disease State(s) Studied (e.g. acute MI, breast cancer, etc.)

  • Hypertension

Study Phase (e.g. Phase I,II,III,IV) Study Phases are defined here

Phase III

Study Design (e.g. multicenter, randomized, double blind, placebo controlled)

Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Study Arms and How They Were Treated (Intervention) (Explanation here)

Drug: Benazepril/amlodipine

Primary Pre-Specified Endpoint

  • Time to having a cardiovascular or neurologic event, including: death from a cardiovascular event, heart attack,
  • stroke, hospitalization for chest pain or heart failure, or
  • procedure to open a blockage in an arterial blood vessel

Secondary Endpoints

  • Time to having a cardiovascular or neurologic event, including: death from a cardiovascular event, heart attack,
  • stroke, or hospitalization for heart failure or or
  • procedure to open a blockage in an arterial blood vessel
  • Risk of developing diabetes
  • Progression of kidney disease

Inclusion Criteria

  • At least 55 years of age.
  • Have elevated blood pressure and at least one other cardiovascular disease or diabetes or evidence of damage to the kidneys, brain, blood vessels or heart as defined in the protocol

Exclusion Criteria

  • Allergy to any of the drugs administered in this trial. Selected laboratory tests
  • Other protocol-defined exclusion criteria may apply.

Outcome: Primary endpoint (Report both relative risk reduction and absolute risk reduction as well as number needed to treat if available)

None reported

Outcome: Secondary endpoint (Report both relative risk reduction and absolute risk reduction as well as number needed to treat if available)

None reported

Outcome: Exploratory endpoints (Report both relative risk reduction and absolute risk reduction as well as number needed to treat if available)

None reported

Outcome: Safety endpoints (Report both relative risk and absolute risk as well as number needed to harm if available)

None reported

Conclusions of the Investigators (Quote the investigators conclusions here)

None reported

Commentary, Discussion and Limitations of the Trial (Anyone can add comments)

None reported

Slides

None reported

Video Commentary

None reported

References (How to insert a reference)

Jamerson K, Weber MA, Bakris GL; et al. (2008). "Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients". N. Engl. J. Med. 359 (23): 2417–28. PMID 19052124. doi:10.1056/NEJMoa0806182. 

External sites for further information (How to insert links)

None reported

Detailed information about the trial

Ages

55 years and older

Gender (Indicate whether men, women or both were enrolled)

Both

Accepts Healthy Volunteers (Answer yes or no)

None reported

Enrollment Period (Study start and end date)

Study start date: October 2003

Recruitment Status (explanation)

Completed

Enrollment (Total number of patients enrolled)

11,464

Study Sponsor (e.g. Investigator initiated or company name)

Novartis Pharmaceuticals

Source of Data (Where is this data on this page coming from: publication, principal investigator, or co-investigator)

Novartis


The content of the clinical trial wiki consists of fields that have been suggested by the World Health Organization and wwww.clinicaltrials.gov.


Linked-in.jpg